TherapeuticsMD Inc (TXMD) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☒ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Form 4 - Statement of changes in beneficial ownership of securities

Current Report Filing (8-k)

false 0000025743 0000025743 2023-06-26 2023-06-26     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  ...

Additional Proxy Soliciting Materials (definitive) (defa14a)

Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC...

Proxy Statement (definitive) (def 14a)

Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC...

Quarterly Report (10-q)

Table of Contents falseQ1--12-310000025743 0000025743 2023-01-01 2023-03-31 0000025743 2023-05-12 0000025743 2023-03-31 0000025743 2022-12-31...

Current Report Filing (8-k)

false 0000025743 0000025743 2023-05-15 2023-05-15     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  ...

TherapeuticsMD Announces First Quarter 2023 Financial Results

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported...

Current Report Filing (8-k)

false 0000025743 0000025743 2023-05-01 2023-05-01     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  ...

Amended Statement of Changes in Beneficial Ownership (4/a)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...